CIPLA Financial Statement Analysis
|
||
|
The Revenues of CIPLA have increased by 6.88% YoY .
The Earnings Per Share (EPS) of CIPLA has decreased by -26.45 % YoY. |
||
CIPLA Last 5 Annual Financial Results
[BOM: 500087|NSE : CIPLA]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹27,548 Cr | ₹25,774 Cr | ₹22,753 Cr | ₹21,763 Cr | ₹19,160 Cr |
| Expenses | ₹20,425 Cr | ₹19,483 Cr | ₹17,763 Cr | ₹17,251 Cr | ₹14,911 Cr |
| Operating Profit (Excl OI) | ₹7,123 Cr | ₹6,291 Cr | ₹4,990 Cr | ₹4,512 Cr | ₹4,249 Cr |
| Other Income | ₹867 Cr | ₹747 Cr | ₹512 Cr | ₹322 Cr | ₹270 Cr |
| Interest | ₹62 Cr | ₹90 Cr | ₹110 Cr | ₹106 Cr | ₹161 Cr |
| Depreciation | ₹1,107 Cr | ₹1,051 Cr | ₹1,172 Cr | ₹1,052 Cr | ₹1,068 Cr |
| Profit Before Tax | ₹6,821 Cr | ₹5,702 Cr | ₹4,038 Cr | ₹3,493 Cr | ₹3,290 Cr |
| Profit After Tax | ₹5,291 Cr | ₹4,155 Cr | ₹2,835 Cr | ₹2,559 Cr | ₹2,401 Cr |
| Consolidated Net Profit | ₹5,273 Cr | ₹4,122 Cr | ₹2,802 Cr | ₹2,517 Cr | ₹2,405 Cr |
| Earnings Per Share (Rs) | ₹48.02 | ₹65.29 | ₹51.05 | ₹34.71 | ₹31.19 |
| PAT Margin (%) | 9.92 | 14.29 | 11.73 | 9.17 | 8.61 |
| ROE(%) | 11.83 | 18.34 | 16.63 | 12.85 | 13.10 |
| ROCE(%) | 16.00 | 23.64 | 22.77 | 18.19 | 17.24 |
| Total Debt/Equity(x) | 0.01 | 0.00 | 0.01 | 0.02 | 0.04 |
Key Financials |
||
| Market Cap | : | ₹ 110,890.7 Cr |
| Revenue (TTM) | : | ₹ 28,162.6 Cr |
| Net Profit(TTM) | : | ₹ 3,869.8 Cr |
| EPS (TTM) | : | ₹ 47.9 |
| P/E (TTM) | : | 28.7 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| CIPLA | -0.3% | -4.1% | -8.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.8% | -4.2% | 7% |
| DIVIS LABORATORIES | 1.1% | -0.7% | -1% |
| TORRENT PHARMACEUTICALS | 0% | 1.3% | 40.1% |
| DR REDDYS LABORATORIES | 0.4% | -4.5% | -5.2% |
| MANKIND PHARMA | -0.6% | -5.9% | 0.1% |
| LUPIN | 1.3% | 0.1% | 13.3% |
| ZYDUS LIFESCIENCES | -1.8% | 6.6% | 10.8% |
| AUROBINDO PHARMA | -4% | -7.7% | 20.2% |
CIPLA Revenues
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 6.88 % |
| 5 Yr CAGR | 9.50 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹27,548 Cr | 6.88 | |
| Mar2025 | ₹25,774 Cr | 13.28 | |
| Mar2024 | ₹22,753 Cr | 4.55 | |
| Mar2023 | ₹21,763 Cr | 13.59 | |
| Mar2022 | ₹19,160 Cr | - | |
CIPLA Operating Profit
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 13.22 % |
| 5 Yr CAGR | 13.79 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹7,123 Cr | 13.22 | |
| Mar2025 | ₹6,291 Cr | 26.07 | |
| Mar2024 | ₹4,990 Cr | 10.60 | |
| Mar2023 | ₹4,512 Cr | 6.20 | |
| Mar2022 | ₹4,249 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 5.94 % |
| 5 Yr CAGR | 3.91 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 25.86% | 5.94 | |
| Mar2025 | 24.41% | 11.31 | |
| Mar2024 | 21.93% | 5.79 | |
| Mar2023 | 20.73% | -6.54 | |
| Mar2022 | 22.18% | - | |
CIPLA Profit After Tax
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 27.93 % |
| 5 Yr CAGR | 21.68 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹5,273 Cr | 27.93 | |
| Mar2025 | ₹4,122 Cr | 47.10 | |
| Mar2024 | ₹2,802 Cr | 11.33 | |
| Mar2023 | ₹2,517 Cr | 4.65 | |
| Mar2022 | ₹2,405 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -30.58 % |
| 5 Yr CAGR | 3.60 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 9.92 % | -30.58 | |
| Mar2025 | 14.29 % | 21.82 | |
| Mar2024 | 11.73 % | 27.92 | |
| Mar2023 | 9.17 % | 6.50 | |
| Mar2022 | 8.61 % | - | |
CIPLA Earnings Per Share (EPS)
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | -26.45 % |
| 5 Yr CAGR | 11.39 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹48 | -26.45 | |
| Mar2025 | ₹65 | 27.89 | |
| Mar2024 | ₹51 | 47.08 | |
| Mar2023 | ₹35 | 11.29 | |
| Mar2022 | ₹31 | - | |
CIPLA Return on Capital Employed (ROCE)
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | -32.32 % |
| 5 Yr CAGR | -1.85 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 16% | -32.32 | |
| Mar2025 | 23.64% | 3.82 | |
| Mar2024 | 22.77% | 25.18 | |
| Mar2023 | 18.19% | 5.51 | |
| Mar2022 | 17.24% | - | |
CIPLA Share Price vs Sensex
| Current Share Price | : | ₹1,372.8 |
| Current MarketCap | : | ₹ 110,890.7 Cr |
| Updated EOD on | : | Jun 16,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -0.3% |
-4.1% |
-8.6% |
| SENSEX | 3.9% |
1.9% |
-6.8% |
CIPLA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE SENSEX 50 | 3.2% | 1.3% | -4.2% |
| BSE 100 | 3.2% | 1.6% | -3.3% |
| BSE SENSEX SIXTY | 3.1% | 1.2% | -4% |
| BSE 100 ESG INDEX | 3.1% | 1.6% | -3.1% |
| BSE 100 LARGECAP TMC INDEX | 3% | 1.4% | -2.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 50 | 3.2% | 1.3% | -4.4% |
| NIFTY 100 | 3.1% | 1.5% | -2.9% |
| NIFTY 200 | 2.8% | 1.5% | -1.7% |
| NIFTY TOTAL MARKET | 2.8% | 1.9% | -1.3% |
| NIFTY 500 | 2.8% | 1.7% | -1.4% |
You may also like the below Video Courses
FAQ about CIPLA Financials
How the annual revenues of CIPLA have changed ?
The Revenues of CIPLA have increased by 6.88% YoY .
How the Earnings per Share (EPS) of CIPLA have changed?
The Earnings Per Share (EPS) of CIPLA has decreased by -26.45 % YoY .
Check out Intrinsic Value of Peers of CIPLA
Compare Stock Analytics of Peers of CIPLA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
